Business
Notice of Preliminary Results 2022
Notice of Preliminary Results 2022.
About this update from Futura Medical Plc
[{"type":"text","content":"\n \n \n \n \n \n \n \n \n 27 March 2023\n \n \n \n \n \n \n \n \n \n Futura Medical plc\n \n \n (\"Futura\" or the \"Company\")\n \n \n \n Notice of Preliminary Results 2022\n \n \n \n \n \n \n Futura Medical plc (AIM: FUM), a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys® drug delivery technology and currently focused on sexual health and pain, will announce its preliminary results for the year ended 31 December 2022 on Wednesday, 5 April 2023.\n \n \n \n \n \n James Barder, Chief Executive Officer, Angela Hildreth, Finance Director and Chief Operating Officer, and Ken James, Executive Director and Head of R&D, will host a webcast for analysts on the day of the results at 10:00am BST, which will be made available within the investor centre section of the Company's website.\n \n \n \n \n \n Please submit questions ahead of the webcast to [email protected] by 10:00am BST on Thursday 30 March 2023. \n \n \n \n \n \n -ENDS-\n \n \n \n \n \n For further information, please contact:\n \n \n \n \n \n \n \n \n Futura Medical plc\n \n \n \n James Barder, Chief Executive Officer\n \n \n Angela Hildreth, Finance Director and COO\n \n \n Email:\n \n [email protected]\n \n \n \n Tel: +44 (0) 1483 685 670\n \n \n \n www.futuramedical.com\n \n \n \n Nominated Adviser and Sole Broker:\n \n \n \n \n \n \n \n \n Liberum\n \n \n \n Phil Walker/ Richard Lindley/ Ben Cryer/ Kane Collings\n \n \n Tel: +44 (0) 20 3100 2000\n \n \n \n \n \n For media enquiries please contact:\n \n \n \n \n \n Optimum Strategic Communications\n \n \n Mary Clark/ Hollie Vile/ Jonathan Edwards/ Zoe Bolt\n \n \n Email: [email protected]\n \n \n Tel: +44 (0) 203 882 9621\n \n \n \n \n \n \n \n \n About Futura Medical plc\n \n \n \n Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a portfolio of innovative products based on its proprietary, transdermal DermaSys®technology. Each DermaSys® formulation is separately patented and specifically tailored for the selected indication and application, as well as being optimised for clinical efficacy, safety, administration and patient convenience. The products are developed for the prescrip...